EI
IMDX

Ellevest Inc’s Insight Molecular Diagnostics IMDX Stock Holding History

Ellevest Inc’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed – – 1574
2021
Q3 		$0 Buy
+3
New +$276 ﹤0.01% 1522

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Ellevest Inc's IMDX Position: Q4 2021 in Review

Ellevest Inc sold out of Insight Molecular Diagnostics (IMDX) in Q4 2021, closing a stake of 3 shares.

Ellevest Inc first reported a position in IMDX in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 88 funds tracked by Wall St. Rank hold IMDX as of Q4 2021.

  • Ellevest Inc reported no remaining Insight Molecular Diagnostics position as of Q4 2021 after selling out during the quarter.
  • Ellevest Inc sold 3 Insight Molecular Diagnostics shares in Q4 2021.
  • Ellevest Inc first reported a position in Insight Molecular Diagnostics in Q3 2021 and held it in 1 quarter.
  • Ellevest Inc's Insight Molecular Diagnostics position peaked at $0 in Q3 2021.
  • 88 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2021.

Based on Ellevest Inc's 13F filing for Q4 2021, filed 24 Jan 2022.